- 5 Ergebnisse
Kleinster Preis: € 149,79, größter Preis: € 196,34, Mittelwert: € 173,10
1
Therapeutic Kinase Inhibitors - Ingo K. Mellinghoff; Charles L. Sawyers
Bestellen
bei Springer.com
€ 149,79
Versand: € 0,001
Bestellengesponserter Link
Ingo K. Mellinghoff; Charles L. Sawyers:

Therapeutic Kinase Inhibitors - neues Buch

ISBN: 9783642282966

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as â??che… Mehr…

new in stock. Versandkosten:zzgl. Versandkosten. (EUR 0.00)
2
Therapeutic Kinase Inhibitors - Ingo K. Mellinghoff; Charles L. Sawyers
Bestellen
bei Springer.com
€ 154,69
Bestellengesponserter Link

Ingo K. Mellinghoff; Charles L. Sawyers:

Therapeutic Kinase Inhibitors - neues Buch

ISBN: 9783642282966

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemo… Mehr…

  - new in stock. Versandkosten:zzgl. Versandkosten.
3
Therapeutic Kinase Inhibitors - Michael Grabinski
Bestellen
bei hive.co.uk
£ 144,93
(ca. € 174,30)
Bestellengesponserter Link
Michael Grabinski:
Therapeutic Kinase Inhibitors - neues Buch

ISBN: 9783642282966

; PDF; Scientific, Technical and Medical > Clinical & internal medicine > Diseases & disorders > Oncology, Gabler Verlag

No. 9783642282966. Versandkosten:Instock, Despatched same working day before 3pm, zzgl. Versandkosten.
4
Therapeutic Kinase Inhibitors - Ingo K. Mellinghoff;  Ingo K. Mellinghoff;  Charles L. Sawyers;  Charles L. Sawyers
Bestellen
bei lehmanns.de
€ 196,34
Versand: € 0,001
Bestellengesponserter Link
Ingo K. Mellinghoff; Ingo K. Mellinghoff; Charles L. Sawyers; Charles L. Sawyers:
Therapeutic Kinase Inhibitors - Erstausgabe

2012, ISBN: 9783642282966

[ED: 1], Auflage, eBook Download (PDF), eBooks, [PU: Springer-Verlag]

  - Versandkosten:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD (EUR 0.00)
5
Therapeutic Kinase Inhibitors - Ingo K. Mellinghoff; Charles L. Sawyers
Bestellen
bei lehmanns.de
€ 190,39
Versand: € 0,001
Bestellengesponserter Link
Ingo K. Mellinghoff; Charles L. Sawyers:
Therapeutic Kinase Inhibitors - neues Buch

2012, ISBN: 9783642282966

2012, eBook Download (PDF), eBooks, [PU: Springer Berlin]

  - Versandkosten:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD. (EUR 0.00)

1Da einige Plattformen keine Versandkonditionen übermitteln und diese vom Lieferland, dem Einkaufspreis, dem Gewicht und der Größe des Artikels, einer möglichen Mitgliedschaft der Plattform, einer direkten Lieferung durch die Plattform oder über einen Drittanbieter (Marketplace), etc. abhängig sein können, ist es möglich, dass die von eurobuch angegebenen Versandkosten nicht mit denen der anbietenden Plattform übereinstimmen.

Bibliographische Daten des bestpassenden Buches

Details zum Buch

Detailangaben zum Buch - Therapeutic Kinase Inhibitors


EAN (ISBN-13): 9783642282966
ISBN (ISBN-10): 3642282962
Erscheinungsjahr: 2012
Herausgeber: Springer Berlin
234 Seiten
Sprache: eng/Englisch

Buch in der Datenbank seit 2012-12-03T21:22:03+01:00 (Zurich)
Detailseite zuletzt geändert am 2023-10-25T14:54:19+02:00 (Zurich)
ISBN/EAN: 3642282962

ISBN - alternative Schreibweisen:
3-642-28296-2, 978-3-642-28296-6
Alternative Schreibweisen und verwandte Suchbegriffe:
Autor des Buches: sawyer, mell, mellin, melling, grabinski
Titel des Buches: kina kina


Daten vom Verlag:

Autor/in: Ingo K. Mellinghoff; Charles L. Sawyers
Titel: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Verlag: Springer; Springer Berlin
234 Seiten
Erscheinungsjahr: 2012-11-27
Berlin; Heidelberg; DE
Sprache: Englisch
149,79 € (DE)
154,00 € (AT)
177,00 CHF (CH)
Available
X, 234 p.

EA; E107; eBook; Nonbooks, PBS / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; B; Cancer Biology; Biomedical and Life Sciences; BB

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.


Includes supplementary material: sn.pub/extras

Weitere, andere Bücher, die diesem Buch sehr ähnlich sein könnten:

Neuestes ähnliches Buch:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))


< zum Archiv...